Evidence map›Paper›PMID 34903548›Full record

ArticleBMJ open2021

Analysis of

Luke C Pilling, Deniz Türkmen, Hannah Fullalove, Janice L Atkins, Joao Delgado, Chia-Ling Kuo, George A Kuchel, Luigi Ferrucci, Jack Bowden, Jane A H Masoli and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06665919 (Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI), which is not on this map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06665919 nacompletednot on this mapstarted 2023, after this paper: background citation

Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI

TypeinterventionalSponsorVistamedi Ltd.Ran2023 to 2025Enrolled283ConditionsCoronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac EventsArmsCYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. The role ofExpert review of clinical pharmacology · 2022
    Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Luke C PillingEpidemiology and Public Health group, College of Medicine and Health, University of Exeter, Exeter, UK l.pilling@exeter.ac.uk.ORCID 0000-0002-3332-8454
Deniz TürkmenEpidemiology and Public Health group, College of Medicine and Health, University of Exeter, Exeter, UK.ORCID 0000-0002-9584-5625
Hannah FullaloveEpidemiology and Public Health group, College of Medicine and Health, University of Exeter, Exeter, UK.
Janice L AtkinsEpidemiology and Public Health group, College of Medicine and Health, University of Exeter, Exeter, UK.ORCID 0000-0003-4919-9068
Joao DelgadoEpidemiology and Public Health group, College of Medicine and Health, University of Exeter, Exeter, UK.ORCID 0000-0003-1648-871X
Chia-Ling KuoConnecticut Convergence Institute for Translation in Regenerative Engineering, University of Connecticut Health, Farmington, Connecticut, USA.
George A KuchelUniversity of Connecticut Center on Aging, University of Connecticut Health, Farmington, Connecticut, USA.
Luigi FerrucciNational Institute on Aging NIA-ASTRA Unit, Harbor Hospital, Baltimore, Maryland, USA.
Jack BowdenExeter Diabetes Group (ExCEED), College of Medicine and Health, University of Exeter, Exeter, UK.
Jane A H MasoliEpidemiology and Public Health group, College of Medicine and Health, University of Exeter, Exeter, UK.
David MelzerEpidemiology and Public Health group, College of Medicine and Health, University of Exeter, Exeter, UK.
University of Exeter · GBUniversity of Connecticut · USMedStar Harbor Hospital · US

Funding

British Heart Foundation CH/1996001/9454Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

objectiveTo determine whether

designRetrospective cohort analysis.

settingPrimary care practices in the UK from January 1999 to September 2017.

participants7483 European-ancestry adults from the UK Biobank study with genetic and linked primary care data, aged 36-79 years at time of first clopidogrel prescription.

interventionsClopidogrel prescription in primary care, mean duration 2.6 years (range 2 months to 18 years).

main outcome measureHospital inpatient-diagnosed ischaemic stroke, MI or angina while treated with clopidogrel.

results28.7% of participants carried at least one C

conclusionsA substantial proportion of the UK population carry genetic variants that reduce metabolism of clopidogrel to its active form. In family practice patients on clopidogrel,

Indexed as

Brain IschemiaStrokeAdultAgedClopidogrelCytochrome P-450 CYP2C19GenotypeHumansMiddle AgedPlatelet Aggregation InhibitorsPrimary Health CareRetrospective StudiesTreatment OutcomeUnited KingdomClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation Inhibitorsepidemiologygeneticsmyocardial infarctionpreventive medicinestroke

Identifiers

PMID34903548
PMCPMC8671970
OpenAlexW4200533780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.